Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | FABP3 | P05413 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13152091 | 0.82 | KDM4E (0.58) | POLBKDM4EATMLMNAKMT2A | |
| SCHEMBL20349882 | 0.78 | RIPK1 (0.43) | KDM4ERIPK1KMT2A | |
| SCHEMBL14215788 | 0.77 | KDM4E (0.56) | POLBKDM4EATMLMNAGAA | |
| SCHEMBL13456694 | 0.77 | ALDH1A1 (0.54) | KDM4ERIPK1KMT2A | |
| SCHEMBL23313034 | 0.77 | KDM4E (0.47) | KDM4ERIPK1LMNAGAA | |
| SCHEMBL23313200 | 0.75 | ALDH1A1 (0.51) | POLBKDM4ERIPK1KMT2AGAA | |
| SCHEMBL6153221 | 0.75 | RIPK1 (0.51) | KDM4ERIPK1LMNAKMT2AGAA | |
| SCHEMBL605325 | 0.74 | KDM4E (0.58) | POLBKDM4EATMLMNAKMT2A | |
| N-Methylanthranilic Acid SCHEMBL10796607 | 0.74 | KDM4E (0.62) | POLBKDM4EATMLMNAKMT2A | |
| SCHEMBL8628627 | 0.73 | POLB (0.67) | POLBKDM4EATMKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | AGTR2, MME, AGTR1 | POLB 4812/4885KDM4E 3004/4885ATM 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.